Company Overview and News
Congress took a big step Tuesday to relax a wave of crisis-era restrictions placed on financial firms, as the House approved a plan to ease rules for small and midsize banks. Full Story
FACEBOOK, INC. is constantly expanding in its Silicon Valley hometown of Menlo Park, California. Now it’s making a bigger push into San Francisco.
The Progressive Corporation (PGR - Free Report) reported earnings per share of 45 cents for April 2018, surging 36% year over year. Moreover, the bottom line is driven by an improved top line. Quarter to date, Progressive’s shares have gained 1.1%, outperforming the industry’s 1.2% decrease. This share price rise was courtesy of the company’s sustained strong results.
Shares of Kemper Corporation (KMPR - Free Report) hit a new 52-week high of $75 on May 16, gaining traction from a strong first-quarter 2018 earnings release. About 0.4 million shares exchanged hands in the last trading session and the stock finally closed at $74.75, inching up 1.7%. The company’s return on equity has been an impressive 9.1% when compared with the industry average of 4.8%. Solid Q1 Results Kemper’s bottom line of $1.
When considering valuation metrics, price-to-earnings ratio has always been the obvious choice as calculations based on earnings are easy and come in handy. However, price-to-sales has emerged as a convenient tool to determine the value of stocks that are incurring losses or are in an early cycle of development, generating meager or no profits.
When considering valuation metrics, price-to-earnings ratio has always been the obvious choice as calculations based on earnings are easy and come in handy. However, price-to-sales has emerged as a convenient tool to determine the value of stocks that are incurring losses or are in an early cycle of development, generating meager or no profits. While a loss-making company with a negative price-to-earnings ratio falls out of investor favor, price-to-sales could indicate the hidden strength of its business.
NEW YORK (Reuters) - American International Group Inc (AIG.N) faces an uphill climb to convince shareholders to approve a $43.1 million pay package for Chief Executive Officer Brian Duperreault during the company’s annual meeting on Wednesday.
(Reuters) - MetLife Inc (MET.N) has entered into an agreement to provide pension benefits for about 41,000 FedEx Corp (FDX.N) retirees and beneficiaries, through a group annuity, the insurer said on Tuesday.
MetLife Inc has entered into an agreement to provide pension benefits for about 41,000 FedEx Corp retirees and beneficiaries, through a group annuity, the insurer said on Tuesday.
DALLAS (Reuters) - Larry Lopata and some friends were sitting around the campfire on a hunting trip when they came up with an idea for a new firearms product: an adjustable-length trigger, so people with different sized hands can comfortably share the same gun.
DALLAS, May 5 (Reuters) - Larry Lopata and some friends were sitting around the campfire on a hunting trip when they came up with an idea for a new firearms product: an adjustable-length trigger, so people with different sized hands can comfortably share the same gun.
Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.
US stocks fell on Wednesday as potential US restrictions on Chinese telecom companies reinforced investor concerns about worsening trade relations between the United States and China.
US stocks fell on Wednesday as potential U.S. restrictions on Chinese telecom companies reinforced investor concerns about worsening trade relations between the United States and China.
The S&P and Dow opened slightly lower on Wednesday as caution set in ahead of the Federal Reserve's decision on monetary policy, while Apple's 3.6 percent jump after results helped small gains on the tech-heavy Nasdaq.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...